T he safety of blood transfusion has been improved markedly owing to advances in blood donor selection and blood testing. Concerns still exist, however, because of a relatively high incidence of bacterial contamination of platelet (PLT) products and the possible risk of transfusion-transmitted infection by emerging pathogens. 1 The adoption of pathogen reduction technologies (PRTs) that broadly and nonspecifically inactivate pathogens is being considered in many countries for the implementation of safer PLT transfusions. The Mirasol PRT (MIR) system (TerumoBCT) uses ultraviolet (UV) light (265-370 nm) and a photosensitizing agent, riboflavin, to irreversibly damage the nucleic acids of infectious agents. 2 The use of such a system is currently approved in some countries for the treatment of PLT concentrates (PCs). 3 Although MIR treatment enhances the safety of PCs, there are concerns about the decrease in product quality. 4 For MIR-treated PCs, several in vitro changes have been reported; they include a decrease in pH, an increase in P-selectin expression level, and the enhancement of glucose consumption and lactate production. The presence of mitochondrial dysregulation 5 and the involvement of p38 mitogen-activated protein kinase (p38MAPK) have also been reported. 6 Clinical findings have included the reduced recovery and survival of MIR-treated PCs 7 or satisfactory hemostatic responses of MIR-treated PLTs isolated from transfused patients. 8 PLTs in blood flow adhere to collagen, which is present at the site of vascular injury, to start thrombus formation. The interaction of the glycoprotein Ib/IX (GPIb/IX) complex with the von Willebrand factor (VWF) is important for PLT adhesion. 9 Moreover, PLTs in blood flow are recruited one after another to be deposited on the PLTs already adhering to collagen, leading to thrombus formation. The binding of activated integrin aIIbb3 to fibrinogen and VWF is essential for PLT deposition. 10 Moreover, the shear stress induced by blood flow is an important factor for both the binding and the dissociation of PLTs during the series of events leading to thrombus formation. 11 The high shear stress itself generated in the vessels with stenosis is considered to activate and aggregate PLTs.
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In our previous study using the collagen column method, we found that MIR treatment affects and enhances the thrombus formation of PLTs. 13 The study also suggested that the enhanced thrombus formation in MIRtreated PLTs highly correlates with the low activation state of aIIbb3, in which aIIbb3 can bind to PAC-1 but cannot sufficiently bind to fibrinogen. However, our study did not show evidence of the direct involvement of aIIbb3 in the enhanced thrombus formation of MIR-treated PLTs. In addition, it did not clarify whether MIR-treated PLTs with high thrombus formation capacity overreact and form thrombi in blood flow without the involvement of collagen.
In this study, we first examined thrombus formation in the presence of an aIIbb3-specific inhibitor by the microchannel method to clarify the relationship between the enhanced thrombus formation and aIIbb3. The microspace in a microchannel makes it possible to achieve an efficient reaction between small amounts of PLT samples and immobilized collagen, thus inducing thrombus formation.
14 A thrombus in the microchannel can be observed under a microscope; therefore, the morphologic change and the kinetic data on thrombus formation can be obtained by fluorescent image analysis. Next, to examine the reactivity of the MIR-treated PLTs in blood flow, shear-induced PLT aggregation (SIPA) level was measured using a cone-plate aggregometer. 15 A wide range of shear stresses including physiologic and pathologic shear stresses can be quantitatively applied to PLTs using a cone-plate aggregometer. We examined the reactivity of MIR-treated PLTs in the absence of exogenous agonists such as collagen.
MATERIALS AND METHODS

Preparation of PCs
Informed consent was obtained from healthy volunteers who fulfilled the Japanese Red Cross blood center criteria for apheresis donation 16 and who participated in this study before the donation. All donors had no history of treatment with anti-PLT agents. Leukoreduced PCs (volume, 225 6 5 mL; yield, 2.4 3 10 11 6 0.1 3 10
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/bag) were collected in an automated blood collection system (Trima Accel, TerumoBCT) or prepared by the leukofiltration of PCs collected in a component collection system (Haemonetics).
MIR treatment
The MIR treatment was carried out in accordance with the manufacturer's instructions (TerumoBCT) within 22 hours on Day 1 postcollection as described elsewhere. [5] [6] [7] [8] Briefly,
after the addition of 35 mL of riboflavin solution to a final concentration of 50 lmol/L, the PC container was exposed to UV light at a dose of 6.24 J/mL (265-370 nm) and allowed to rest for 30 minutes before placing it on a flatbed shaker with reciprocal agitation (50-60 cycles/min) for 1 hour at 20 to 248C away from direct light sources. For in vitro PLT function measurements, a 5-mL aliquot was sampled from the same PC container before and after MIR treatment. PLT samples before MIR treatment were used as a control. In this study, only the early effect of MIR treatment was evaluated without considering PLT storage lesions.
PLT thrombus formation and thrombus stability assay by microchannel method Figure 1 shows a schematic of the assessment of thrombus formation and thrombus stability by the microchannel method. The inner wall of the microchannel plate (l-slide VI, Ibidi) was coated with 20 lg/mL Type I acid-insoluble collagen fibrils from a bovine Achilles tendon (SigmaAldrich). To examine PLT function under close to physiologic condition, PLT-rich plasma (PRP) was adjusted from PCs to 30 3 10 10 PLTs/L by dilution with autologous plasma. PRP was incubated for 10 minutes at 378C with or without 2 lmol/L tirofiban (Sigma-Aldrich), an aIIbb3-specific inhibitor. PRP was then incubated in the microchannel for 10 minutes at 378C to induce thrombus formation. The thrombus formed was fixed with 1% paraformaldehyde phosphate-buffered saline (PBS) at room temperature for 1 hour and then fluorescently stained with a monoclonal Alexa Fluor 488-conjugated anti-CD41 antibody (MEM-06, EXBIO). A fluorescent image of the thrombus formed in the microchannel was observed by fluorescence microscopy (IX-71, Olympus) at 1003 magnification. The obtained fluorescent image was presented as an intensity profile image showing the distribution of fluorescence intensity. The PLT surface coverage and the total amount of PLTs deposited (hereafter, total deposition) were calculated from three representative images using Lumina Vision software (Mitani). A fixed threshold of 10 to 255 arbitrary fluorescence units was used to define PLT adherence allowing us to determine the percentage of pixels covered by PLTs in the measurement field. In an experiment, PBS was used to flush the microchannel after thrombus formation at shear rates of 100 and 1500/sec for 15 minutes at 378C to assess the stability of the thrombus against the blood flow. The percentage of dissociated PLTs was calculated from the difference in total deposition before and after flushing and was used as an indicator of thrombus stability.
Measurement of SIPA level
SIPA level was measured using a cone-plate shearinduced PLT aggregometer (Finggal Link) as described elsewhere. 15 Similarly to the case of using a common agonist-induced PLT aggregometer, SIPA level was determined on the basis of the increase in light transmittance while shear stress was applied to PRP in the cone-plate aggregometer in a specific pattern over time at 6 to 108 dyn/cm 2 at 378C. After the measurement of SIPA level, some samples were fixed with 1% paraformaldehyde PBS at room temperature for 1 hour and the images of the PLT aggregate were then obtained by phase contrast microscopy (BX-51, Olympus) at 4003 magnification.
Statistical analysis
Results are shown as mean 6 SD. Significance was determined by t test with p values of less than 0.05 determined to be significant.
RESULTS
Effects of MIR treatment on PLT thrombus formation
PLT thrombus formation on collagen was compared before and after MIR treatment by the microchannel method.
There was a much larger number of MIR-treated PLTs than of control PLTs binding to collagen in the microchannel ( Fig.  2A) . From the fluorescent images of the thrombi formed, there was no significant difference in surface coverage between MIR-treated PLTs and control PLTs on collagen. On the other hand, the total deposition of MIR-treated PLTs on collagen was significantly higher than that of control PLTs (Fig. 2B ). These findings suggest that MIR treatment enhanced the thrombus formation of PLTs on collagen and that the enhancement was caused by PLT deposition rather than by the adhesion of PLTs to the collagen surface.
Relationship between enhancement of thrombus formation and aIIbb3
In thrombus formation, integrin aIIbb3 in PLTs is an important molecule that binds to fibrinogen and VWF and promotes PLT deposition. In this study, the aIIbb3 inhibitor was used to determine whether the promotion of PLT deposition by MIR treatment was mediated by aIIbb3. The deposition of both MIR-treated and control PLTs on the collagen surface was significantly inhibited in the presence of tirofiban, a potent aIIbb3 inhibitor (Figs. 3A and 3B). The promotive effect of MIR treatment on PLT deposition completely disappeared. These findings suggest that MIR treatment enhances PLT deposition on the adherent PLTs via aIIbb3.
Effects of MIR treatment on PLT thrombus stability
To determine the stability of a thrombus on the collagen surface in blood flow, PBS was applied to flush the thrombus in the microchannel at shear rates of 100 and 1500/ sec for 15 minutes and the dissociation of the deposited PLTs was observed. After flushing, the number of remaining undissociated PLTs decreased throughout the thrombus for both MIR-treated and control PLTs (Fig. 4A) . However, as shown in Fig. 4B , the percentage of the dissociation of MIR-treated PLTs (13.2 6 4.2%) was significantly lower than that of control PLTs (35.9 6 12.4%) at a shear rate of 1500/sec. In contrast, there was no significant difference in the percentage of the dissociation between MIR- treated PLTs (6.0 6 5.5%) and control PLTs (9.2 6 6.2%) at a shear rate of 100/sec. These findings suggest that MIR treatment stabilizes PLT thrombi in blood flow, especially under a high-shear condition.
Effects of MIR treatment on SIPA
To estimate the reactivity of MIR-treated PLTs in the blood flow without collagen, the aggregation of MIR-treated PLTs was examined by quantitatively applying shear stress to PLTs. At a low shear stress of 6 to 12 dyn/cm 2 , a slight reversible increase in light transmittance was observed for MIR-treated PLTs. On the other hand, at a high shear stress of 108 dyn/cm 2 , the light transmittance significantly increased for control PLTs but not for MIR-treated PLTs (Fig. 5A) . After SIPA, the size of aggregates of control PLTs was large, but that of MIR-treated PLTs was negligible (Fig. 5B) . The reversible aggregation was slightly potentiated at a low shear stress in MIR-treated PLTs. In contrast, the irreversible aggregation was considerably inhibited at a high shear stress in MIR-treated PLTs (Fig.   5C ). These findings suggest that in the absence of collagen, MIR treatment significantly decreased PLT reactivity particularly under high-shear-stress conditions. 
DISCUSSION
We evaluated the effects of MIR treatment on PLT thrombus formation by the microchannel method. Similarly to our previous study using the collagen column method, 13 the enhanced thrombus formation was observed for the MIR-treated PLTs on immobilized collagen. Moreover, from the fluorescent image of thrombus, it was confirmed that this enhancement did not occur in the early phase of thrombus formation, during which PLTs adhered to the collagen surface, but occurred during the subsequent enhanced PLT deposition on the adherent PLTs. These results agreed with the report of thrombus formation in an experiment using rabbit aorta segments, 17 suggesting that MIR treatment does not affect the contact and adhesion of PLTs on collagen but affects the three-dimensional formation of thrombi. PLT adhesion and deposition (aggregation) are often considered as distinct processes in thrombus formation on collagen. PLTs directly and indirectly adhere to collagen with at least three receptors, GPIb/IX complex via VWF, a2b1, and GPVI, 18 whereas
PLTs mainly deposit with aIIbb3 via fibrinogen and VWF. MIR treatment may not affect the binding of PLTs to collagen. We examined whether aIIbb3 was involved in the promotion of MIR-treated PLT deposition. Upon PLT activation, aIIbb3 undergoes conformational changes to bind to fibrinogen and VWF. As a result, the PLTs aggregate to form a large, three-dimensional thrombus, which is necessary for hemostasis. 10, 19, 20 In the presence of the aIIbb3-specific inhibitor, the thrombus formation by MIR-treated PLTs was inhibited similarly to that by control PLTs, and the promotive effect of MIR treatment on PLT deposition completely disappeared. Namely, the thrombus formation of MIR-treated PLTs was enhanced by the promotion of PLT deposition on the PLTs already adhering to the collagen surface, which was mediated by the binding of aIIbb3 to ligands such as fibrinogen and VWF. MIR treatment includes UV light irradiation in a wide range of wavelengths from UV-C to UV-A (265-370 nm). 21 We previously showed that the binding of PAC-1, an antibody that specifically recognizes the active conformation of aIIbb3, was significantly enhanced for MIR-treated PLTs compared with control PLTs (85.3 6 9.4% vs. 10.7 6 7.1% positive cells). 13 Similar results have been described by other groups. 22, 23 These results suggest that direct aIIbb3 activation induced by UV light irradiation as part of the MIR system affects PLT deposition and the subsequent thrombus formation. We next examined the stability of the thrombi formed by MIR-treated PLTs. Thrombus formation proceeds with the repeated binding and dissociation of PLTs in blood flow. 24 It was reported that, during this process, the shear stress caused by blood flow dissociates PLTs from the surface of subendothelial tissues such as collagen and Values are expressed as mean 6 SD. *p < 0.01.
VWF. 25, 26 In this study, the dissociation of MIR-treated
PLTs from thrombi was examined by quantitatively applying a flow simulating blood flow to the thrombus. The results revealed that the thrombi formed by MIR-treated PLTs were more stable in blood flow than those formed by control PLTs. Goto and colleagues, 27 who used a flow chamber, reported that sustaining aIIbb3 activation after the intracellular Ca level increase is necessary for stabilizing thrombi in blood flow. The aIIbb3 activation by MIR treatment may not only be involved in the enhancement of thrombus formation but also in the thrombus stability in blood flow. Finally, we examined the reactivity of MIR-treated PLTs in the absence of collagen to estimate the behavior of MIR-treated PLTs in the blood flow at the site without vascular injury. The PLTs in blood flow are exposed to a wide range of shear stresses. Exposure of PLTs to shear stress leads to their activation and aggregation in the absence of exogenous agonists, particularly under highshear-stress conditions that may reflect those in the vessels with stenosis. 15, 28, 29 The aggregation level of MIRtreated PLTs in the presence of shear stress alone without agonists was evaluated in this study. The results indicate that the MIR treatment causes a slight reversible aggregation of PLTs at low shear stresses of 6 to 12 dyn/cm 2 , whereas it caused negligible aggregation at a high shear stress of 108 dyn/cm 2 . SIPA under low-shear-stress conditions occurs through the binding of aIIbb3 to fibrinogen; however, this aggregation does not occur at the physiologic Ca level in plasma and is considered to have little physiologic significance. 15 On the other hand, the aggregation under high-shear-stress conditions occurs through the binding of aIIbb3 and the GPIb/IX complex to VWF. 15, 28 However, the high shear stress of 108 dyn/cm 2 only exists at the site of arterial stenosis. Although the reason behind the decreased aggregation level of MIR-treated PLTs at a high shear stress remains unclear, the reactivity of MIRtreated PLTs in the blood flow not in contact with collagen seemed to be lower than that of control PLTs. It has been reported that MIR-treated PLTs are likely to aggregate spontaneously owing to stirring or shaking and tend to form aggregates in PCs. 3, 30 We consider that this phenomenon may represent microaggregation, which is observed during SIPA at a low shear stress. It was reported that the aggregates formed at a low shear stress disappear in plasma with normal Ca level. 15 Considering this observation, spontaneous aggregation observed in MIR-treated PLTs may occur because of the Ca level in PCs being kept lower than that in vivo by ACD, which has yet to be confirmed experimentally. This spontaneous aggregation of MIR-treated PLTs should be taken into consideration in terms of the quality of PLT preparations and the risk of intravascular formation of thrombi. However, this aggregation may be associated with only a low risk of thrombosis because the small aggregates reversibly dissociate, as observed in the measurement of SIPA level. There have been no findings indicating the risk of thrombus formation in clinical trials using MIR-treated PLTs.
We have already suggested that, although the PAC-1 binding level is high in MIR-treated PLTs, this high PAC-1 binding level does not correlate with fibrinogen binding level and that the MIR-treated PLTs per se show a low activation level of aIIbb3 in the absence of its agonist. 13 It has been reported that integrins exist in at least three conformational states depending on the activation level, 31 and MIR treatment likely causes only a slight conformational change of aIIbb3 that is recognizable by the PAC-1 antibody. The low activation level of aIIbb3 induced by MIR treatment may be insufficient for fibrinogen binding and subsequent PLT aggregation in the absence of collagen. Arthur and colleagues 32 reported that ligation of the PLT-specific collagen receptor GPVI/FcR leads to aIIbb3 activation via spleen tyrosine kinase (Syk)-dependent and Syk-independent pathways. The risk of spontaneous induction of thrombosis is considered to be low unless aIIbb3 is sufficiently activated by exogenous agonists such as collagen. Experiments using turbidometric aggregometry in which PLTs are simply stirred in the presence of soluble agonists such as collagen and thrombin receptor-activating peptide (TRAP) showed a low aggregation level of MIR-treated PLTs. 33, 34 In contrast, the microchannel method was designed to assess in vitro thrombus formation on immobilized collagen, a condition more physiologic than turbidometric aggregometry. Studies of the function of MIR-treated PLTs using flow cytometry-based PLT aggregation assay 3 or Impact-R (DiaMed), which reflects PLT adhesion on the surface coated with plasma proteins at a constant shear rate, 33 indicated that the thrombus formation capacity of MIR-treated PLTs is higher than that of control PLTs, which agrees with our results. In this study, thrombus formation was measured by the microchannel method as an index of PLT function. In the microchannel method, although hemostasis is a complicated process involving many mechanisms, only the reaction between PLTs and collagen, the major component of the subendothelium, was evaluated in the absence of RBCs. Moreover, how the reaction between PLTs and collagen leads to the enhancement of thrombus formation via aIIbb3 on MIR-treated PLTs has not been clarified by our study. In addition, although the safety of MIR-treated PLTs in the blood flow was examined by assessing the SIPA in this study, the results did not reflect the interaction of MIR-treated PLTs with other blood cells or vessels in the blood flow. It has been reported that MIR-treated PLTs affect the cytokine production of mononuclear cells. 35 The safety of MIR-treated PLTs should be examined further in future studies.
In conclusion, we observed the enhanced thrombus formation by MIR-treated PLTs by the microchannel method. This enhancement is considered to be caused by the promotion of three-dimensional PLT deposition, which was mediated by aIIbb3. The thrombi formed by MIR-treated PLTs were very stable in a stream simulating the blood flow. Moreover, MIR-treated PLTs did not aggregate under high-shear-stress conditions. The reactivity of MIR-treated PLTs seemed to be rather low in the absence of an agonist such as collagen. MIR treatment slightly augmented the ability of aggregation under low-shearstress conditions. Ultimately, the clinical impacts of these in vitro findings on the hemostatic potential of MIRtreated PLTs should be evaluated in appropriate clinical settings.
